SER150

From WikiProjectMed
Jump to navigation Jump to search

SER150 (formerly EV 077) is an inhibitor of thromboxane synthase and an antagonist of the thromboxane prostanoid receptor. It was developed for diabetic nephropathy.[1][2][3]

References

  1. ^ Kim, Yoon Kook; Ning, Xinyuan; Munir, Kashif M.; Davis, Stephen N. (2 October 2022). "Emerging drugs for the treatment of diabetic nephropathy". Expert Opinion on Emerging Drugs. 27 (4): 417–430. doi:10.1080/14728214.2022.2155632.
  2. ^ McFarlane, Samy I. (2020). Kidney Disease in Diabetes. Bentham Science Publishers. p. 101. ISBN 978-981-14-2199-0.
  3. ^ Tan, Seng Kiong; Cooper, Mark E. (28 October 2023). "Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?". Expert Opinion on Emerging Drugs. 28 (4): 217–226. doi:10.1080/14728214.2023.2277762.
Retrieved from "https://mdwiki.org/wiki/SER150"